Shrinkwrapped looks at the legislation from a practitioner's viewpoint:
Hidden within the new healthcare bill is a change in status for insurance companies from independent, for profit entities, to something more along the lines of a public utility, with rates set by anonymous boards, insulated from public reaction by the usual layers of bureaucratic obfuscatory edifices. Insurance companies have always defaulted in their rates to converge on Medicare fees. With the new government control of the insurers (who gain a new, captive group of healthy rate payers, ie guaranteed profits, while giving up risk and freedom; the insurance companies are not at all unhappy with the bill and that should be informative) we will all be the beneficiaries of a system which is designed to see patients and Doctors as adversaries costing money for no benefit to the bureaucracy.
It is difficult for me to see how this can be anything but bad news for progress in both pharmaceuticals and medical devices. Innovation just complicates the lives of these bureaucracies, raising unpleasant problems of cost and access. Nobody needs it but the patients, and they won't vote when they're dead anyway.